ArticleNanomaterials (Basel, Switzerland)2022
Inhibiting Metastasis and Improving Chemosensitivity via Chitosan-Coated Selenium Nanoparticles for Brain Cancer Therapy.
Article in Nanomaterials (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Development and Characterization of a Guar Gum Bionanocomposite Loaded with Biogenic Selenium Nanoparticles and Its Cytotoxic Evaluation.Gels (Basel, Switzerland) · 2026Article
- Overview of Ferroptosis in Cadmium Toxicity.Biological trace element research · 2026Review
- Green-Synthesized Selenium Nanoparticles Incorporated in Alginate/Casein Hydrogel for Targeted Cancer Therapy: Enhancing Therapeutic Index and Reducing Toxicity.Cell biochemistry and biophysics · 2026Article
- Small Particles, Big Impact: Inorganic Nanotechnology for Glioblastoma.Molecules (Basel, Switzerland) · 2026Review
- Antiviral activity of green synthesized selenium nanoparticles alone and in combination with chitosan against SARS-CoV-2.Discover nano · 2026Article
- Engineering biopolymer-based nanocarriers for cancer drug delivery: a system-level comparison of chitosan, hemicellulose, and lignin platforms with focus on tumor targeting, biodegradation, and immune modulation.Frontiers in bioengineering and biotechnology · 2026Review
- Selenium Nanoparticles as Versatile Delivery Tools.Pharmaceutics · 2025Review
- Coumarins in Anticancer Therapy: Mechanisms of Action, Potential Applications and Research Perspectives.Pharmaceutics · 2025Review
- Utilization of nanotechnology to surmount the blood-brain barrier in disorders of the central nervous system.Materials today. Bio · 2025Review
- Plant Extracts for Production of Functionalized Selenium Nanoparticles.Materials (Basel, Switzerland) · 2024Review
- The Application of Ultrasmall Gold Nanoparticles (2 nm) Functionalized with Doxorubicin in Three-Dimensional Normal and Glioblastoma Organoid Models of the Blood-Brain Barrier.Molecules (Basel, Switzerland) · 2024Article
- Editorial for Special Issue "Cancer Treatment via Nanotherapy".Nanomaterials (Basel, Switzerland) · 2023Article
- The Refined Application and Evolution of Nanotechnology in Enhancing Radiosensitivity During Radiotherapy: Transitioning from Gold Nanoparticles to Multifunctional Nanomaterials.International journal of nanomedicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Selenium nanoparticles (SeNPs) were synthesized to overcome the limitations of selenium, such as its narrow safe range and low water solubility. SeNPs reduce the toxicity and improve the bioavailability of selenium. Chitosan-coated SeNPs (Cs-SeNPs) were developed to further stabilize SeNPs and to test their effects against glioma cells. The effects of Cs-SeNPs on cell growth were evaluated in monolayer and 3D-tumor spheroid culture. Cell migration and cell invasion were determined using a trans-well assay. The effect of Cs-SeNPs on chemotherapeutic drug 5-fluorouracil (5-FU) sensitivity of glioma cells was determined in tumor spheroids. An in vitro blood-brain barrier (BBB) model was established to test the permeability of Cs-SeNPs. SeNPs and Cs-SeNPs can reduce the cell viability of glioma cells in a dose-dependent manner. Compared with SeNPs, Cs-SeNPs more strongly inhibited 3D-tumor spheroid growth. Cs-SeNPs exhibited stronger effects in inhibiting cell migration and cell invasion than SeNPs. Improved 5-FU sensitivity was observed in Cs-SeNP-treated cells. Cellular uptake in glioma cells indicated a higher uptake rate of coumarin-6-labeled Cs-SeNPs than SeNPs. The capability of coumarin-6 associated Cs-SeNPs to pass through the BBB was confirmed. Taken together, Cs-SeNPs provide exceptional performance and are a potential alternative therapeutic strategy for future glioma treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.